Relmada Therapeutics received a notice from Nasdaq stating that its stock price has been below $1 for 30 consecutive business days and has a 180-day compliance period to regain compliance or face potential delisting.
AI Assistant
RELMADA THERAPEUTICS INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.